Swedbank AB Acquires 121,500 Shares of Lantheus Holdings, Inc. $LNTH

Swedbank AB boosted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 11.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,228,743 shares of the medical equipment provider’s stock after purchasing an additional 121,500 shares during the period. Swedbank AB’s holdings in Lantheus were worth $119,925,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in LNTH. Baird Financial Group Inc. grew its position in Lantheus by 579.7% in the fourth quarter. Baird Financial Group Inc. now owns 2,277 shares of the medical equipment provider’s stock valued at $204,000 after purchasing an additional 1,942 shares in the last quarter. Cetera Investment Advisers grew its position in Lantheus by 22.7% in the fourth quarter. Cetera Investment Advisers now owns 23,358 shares of the medical equipment provider’s stock valued at $2,090,000 after purchasing an additional 4,320 shares in the last quarter. Gotham Asset Management LLC grew its position in Lantheus by 4.8% in the fourth quarter. Gotham Asset Management LLC now owns 12,905 shares of the medical equipment provider’s stock valued at $1,154,000 after purchasing an additional 596 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in Lantheus in the fourth quarter valued at $2,406,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Lantheus by 4.1% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 39,212 shares of the medical equipment provider’s stock valued at $3,508,000 after purchasing an additional 1,531 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Stock Performance

Shares of LNTH stock opened at $52.94 on Friday. The stock has a market cap of $3.60 billion, a P/E ratio of 14.08 and a beta of 0.15. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.29 and a quick ratio of 4.07. The company has a fifty day moving average price of $63.98 and a two-hundred day moving average price of $81.36. Lantheus Holdings, Inc. has a one year low of $47.25 and a one year high of $118.21.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.08). The firm had revenue of $378.05 million during the quarter, compared to analyst estimates of $389.69 million. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The business’s revenue was down 4.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.80 EPS. As a group, equities analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Analyst Ratings Changes

LNTH has been the subject of a number of analyst reports. William Blair reaffirmed a “market perform” rating on shares of Lantheus in a research report on Wednesday, July 16th. JMP Securities decreased their target price on shares of Lantheus from $112.00 to $73.00 and set a “market outperform” rating for the company in a research report on Thursday, August 7th. Truist Financial set a $63.00 price target on shares of Lantheus and gave the company a “hold” rating in a research note on Monday, August 11th. B. Riley cut their price target on shares of Lantheus from $122.00 to $109.00 and set a “buy” rating for the company in a research note on Monday, June 23rd. Finally, Mizuho cut their price target on shares of Lantheus from $120.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, August 7th. Four investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $91.60.

Insider Transactions at Lantheus

In other news, insider Rajiv A. Patel sold 3,365,000 shares of the firm’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the sale, the insider owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. This trade represents a 49.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the firm’s stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the sale, the insider owned 3,477,227 shares of the company’s stock, valued at approximately $195,246,296.05. This represents a 49.18% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 6,812,000 shares of company stock valued at $382,427,380. 1.50% of the stock is currently owned by corporate insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.